8-K: Aquestive Therapeutics Reports Positive Q2 Results, Advances Key Pipeline Programs

Aquestive Therapeutics announced its second quarter 2024 financial results, highlighting progress in its Anaphylm and Libervant programs and a strengthened cash position.

Summary

• Aquestive Therapeutics reported a 52% increase in total revenue to $20.1 million in the second quarter of 2024, up from $13.2 million in the same period last year.
• The company's net loss for the quarter was $2.7 million, or $0.03 per share, an improvement from a $5.8 million loss, or $0.10 per share, in the second quarter of 2023.
• Non-GAAP adjusted EBITDA income was $1.8 million for the quarter, compared to a $3.3 million loss in the same quarter of the previous year.
• Aquestive finished the second quarter with approximately $90 million in cash and cash equivalents, reaffirming its cash runway into 2026.
• The company is advancing its Anaphylm sublingual film for severe allergic reactions, with a planned NDA submission in the first quarter of 2025 and a potential launch at the end of 2025 or early 2026.
• Positive topline data was reported from temperature/pH and self-administration studies for Anaphylm.
• Libervant buccal film for seizure clusters in patients aged two to five years has been launched, with national retail distribution expected in the fourth quarter of 2024.
• The company is also progressing its AQST-108 topical gel for dermatology conditions, with a pre-IND meeting planned for the fourth quarter of 2024 and a phase 2a study in the first half of 2025.
• Aquestive updated its full-year 2024 revenue guidance to $57 to $60 million and non-GAAP adjusted EBITDA loss to $20 to $23 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved profitability, and significant progress in key pipeline programs. The company's strengthened cash position and clear timelines for upcoming milestones also contribute to the positive outlook.

Positives

• The company experienced a significant increase in revenue, driven by license and royalty revenue.
• The net loss decreased substantially year-over-year, indicating improved financial performance.
• Aquestive achieved positive non-GAAP adjusted EBITDA, a significant turnaround from the previous year.
• The company has a strong cash position, providing a runway into 2026.
• Positive clinical trial results for Anaphylm support its potential as an alternative to existing epinephrine treatments.
• The launch of Libervant for young patients is progressing well, with expanded sales and distribution plans.
• The company is actively advancing its pipeline, including AQST-108, with clear timelines for regulatory milestones.
• The company successfully completed a $77.5 million underwritten public offering, strengthening its balance sheet.

Negatives

• Manufacture and supply revenue decreased to $8.1 million in Q2 2024 from $11.6 million in Q2 2023, due to timing of orders.
• Selling, general and administrative expenses increased to $11.4 million in Q2 2024 from $7.4 million in Q2 2023, driven by commercial spending and regulatory fees.
• The company is still operating at a net loss, although it has improved significantly.
• The company is subject to an orphan drug market exclusivity block for Libervant in patients 12 years and older until January 2027.

Risks

• There are risks associated with the development and regulatory approval of Anaphylm, AQST-108, and Libervant for older patients.
• The company faces competition from existing products and potential generics.
• There is a risk that the company may not overcome the orphan drug exclusivity for Libervant in older patients.
• The company needs to successfully commercialize Libervant and develop a sales and marketing capability for Anaphylm.
• There are risks related to manufacturing capabilities and the ability to meet demand for its products.
• The company is subject to risks related to intellectual property rights and potential infringement claims.
• The company is subject to risks related to general economic, political, business, industry, regulatory, financial and market conditions.

Future Outlook

Aquestive updated its full-year 2024 financial guidance, projecting total revenues of $57 to $60 million and a non-GAAP adjusted EBITDA loss of $20 to $23 million. The company anticipates submitting an NDA for Anaphylm in the first quarter of 2025 and launching the product at the end of 2025 or early 2026, if approved. They also plan to expand the sales and distribution of Libervant and advance AQST-108 through clinical development.

Management Comments

• Daniel Barber, President and CEO of Aquestive, stated that the company is rapidly transforming through advancing its epinephrine prodrug platform.
• Mr. Barber believes Anaphylm has the potential to be a billion-dollar commercial opportunity.
• Management believes the Adrenaverse platform could produce another billion dollars in opportunities if new product candidates are approved.

Industry Context

This announcement comes as the pharmaceutical industry continues to focus on innovative drug delivery methods and treatments for severe allergic reactions and epilepsy. Aquestive's progress with Anaphylm and Libervant positions it as a key player in these areas, potentially disrupting the market for traditional epinephrine injectors and seizure rescue medications. The company's focus on oral film technology aligns with the trend towards patient-friendly and convenient drug administration.

Comparison to Industry Standards

• Aquestive's Anaphylm is being developed as an alternative to EpiPen and other injectable epinephrine products, which are the current standard of care for anaphylaxis. The company's sublingual film technology offers a potentially more convenient and user-friendly option.
• Libervant is positioned as an alternative to device-based seizure rescue products like rectal gels and nasal sprays, aiming to provide a more patient-friendly oral administration method. Competitors in the seizure rescue market include products like Valtoco (diazepam nasal spray) and Diastat (diazepam rectal gel).
• The company's manufacturing capabilities and collaborations are similar to other pharmaceutical companies that license and supply products, such as Catalent and Lonza, but Aquestive focuses on its proprietary film technology.
• Aquestive's revenue growth of 52% year-over-year is a strong performance compared to the average growth rate of many small to mid-sized pharmaceutical companies, which often struggle to achieve such rapid expansion.
• The company's non-GAAP adjusted EBITDA turning positive is a significant improvement compared to many biotech companies that are still in the development phase and are not yet profitable.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, improved profitability, and positive clinical trial results.
• Employees may see increased job security and opportunities due to the company's growth.
• Patients will have access to new and potentially more convenient treatment options for severe allergic reactions and seizure clusters.
• Customers will benefit from the expanded distribution and availability of Libervant.
• Suppliers may see increased demand for their products as Aquestive's manufacturing operations grow.
• Creditors may have increased confidence in the company's ability to meet its financial obligations due to its improved financial performance.

Next Steps

• Aquestive plans to submit a pre-NDA meeting request letter to the FDA for Anaphylm in the third quarter of 2024.
• The company will commence a single-dose pediatric study for Anaphylm immediately following the pre-NDA meeting.
• Aquestive plans to begin the NDA submission for Anaphylm before the end of 2024 and complete it in the first quarter of 2025.
• The company will expand its sales coverage for Libervant to a national team of up to 10 sales representatives by the fourth quarter of 2024.
• Aquestive expects to have national retail distribution for Libervant in place by the fourth quarter of 2024.
• The company plans to hold a pre-IND meeting with the FDA for AQST-108 in the fourth quarter of 2024.
• Aquestive is planning a phase 2a study for AQST-108 in the first half of 2025.
• The company plans to hold an investor day in the coming months to communicate the science and intellectual property of the Adrenaverse platform.

Key Dates

Keywords

Anaphylm, Libervant, epinephrine, seizure clusters, pharmaceutical, FDA, clinical trials, drug delivery, revenue, EBITDA, AQST-108, Adrenaverse